stocks logo

ITCI

Intra-Cellular Therapies Inc
$
0.000
-131.87(-100.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
7.49B
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
105.57M
EV
13.05B
EV/OCF(TTM)
--
P/S(TTM)
19.98
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q2
FY2025Q1
238.74M
+36.13%
--
--
222.46M
+37.84%
--
--
205.53M
+41.87%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Intra-Cellular Therapies, Inc. (ITCI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by %.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
13 Analyst Rating
up Image0
Wall Street analysts forecast ITCI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITCI is 130.83 USD with a low forecast of 118.00 USD and a high forecast of 132.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
9 Hold
0 Sell
Moderate Buy
up Image0
Current: 0
sliders
Low
118.00
Averages
130.83
High
132.00
Cantor Fitzgerald
Charles Duncan
Hold
Reiterates
$132
2025-04-02
Reason
Mizuho
Graig Suvannavejh
Buy
to
Hold
Downgrades
$140 → $132
2025-02-24
Reason
Mizuho analyst Graig Suvannavejh downgraded Intra-Cellular (ITCI) to Neutral from Outperform with a price target of $132, down from $140, after Johnson & Johnson (JNJ) agreed to acquire all of the company's outstanding shares for $132 in cash. The firm sees no reason for the pending takeover deal to get blocked, especially in light of recent precedent transactions. In addition, another bidder is unlikely to emerge at this point, the analyst tells investors in a research note.
Needham
Ami Fadia
Hold
Reiterates
n/a
2025-02-21
Reason
Canaccord Genuity
Sumant Kulkarni
Strong Buy
to
Hold
Downgrades
$119 → $132
2025-01-31
Reason
Canaccord downgraded Intra-Cellular (ITCI) to Hold from Buy with a price target of $132, up from $119, after Johnson & Johnson (JNJ) agreed to acquire all of the company's outstanding shares for $132 per share in cash.
RBC Capital
Brian Abrahams
Buy
to
Hold
Downgrades
$108 → $132
2025-01-22
Reason
RBC Capital analyst Brian Abrahams downgraded Intra-Cellular (ITCI) to Sector Perform from Outperform with a price target of $132, up from $108, to reflect the proposed takeover by Johnson & Johnson (JNJ). The firm expects the stock to trade roughly in line with the proposed acquisition price going forward. RBC sees relatively limited risk of regulatory hurdles that would otherwise derail the proposed acquisition.
Piper Sandler
David Amsellem
Buy
to
Hold
Downgrades
$107 → $132
2025-01-14
Reason

Valuation Metrics

The current forward P/E ratio for Intra-Cellular Therapies Inc (ITCI.O) is 494.08, compared to its 5-year average forward P/E of -44.35. For a more detailed relative valuation and DCF analysis to assess Intra-Cellular Therapies Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-44.35
Current PE
494.08
Overvalued PE
73.92
Undervalued PE
-162.62

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-65.30
Current EV/EBITDA
-1029.63
Overvalued EV/EBITDA
87.17
Undervalued EV/EBITDA
-217.77

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
16.67
Current PS
14.76
Overvalued PS
24.17
Undervalued PS
9.18

Financials

Annual
Quarterly
FY2024Q4
YoY :
+50.81%
199.22M
Total Revenue
FY2024Q4
YoY :
-14.37%
-29.20M
Operating Profit
FY2024Q4
YoY :
-40.92%
-16.89M
Net Income after Tax
FY2024Q4
YoY :
-46.67%
-0.16
EPS - Diluted
FY2024Q4
YoY :
+534.24%
-13.08M
Free Cash Flow
FY2024Q4
YoY :
-2.33%
89.76
Gross Profit Margin - %
FY2024Q4
YoY :
-59.70%
-10.80
FCF Margin - %
FY2024Q4
YoY :
-60.80%
-8.48
Net Margin - %

Trading Trends

Insider
Insiders areSelling! The selling amount has increased 136.25% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
12.4M
USD
4
0-12
Months
22.6M
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
530.9K
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
399.3K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
56.0K
USD
7
6-9
Months
16.0K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ITCI News & Events

Events Timeline

2025-04-22 (ET)
2025-04-22
08:30:04
Thirteen option delistings on April 22nd
select
2025-02-21 (ET)
2025-02-21
08:03:24
Intra-Cellular reports Q4 EPS (16c), consensus (11c)
select
2025-01-13 (ET)
2025-01-13
05:33:32
Johnson & Johnson to acquire Intra-Cellular for $132.00 per share in cash
select
Sign Up For More Events

News

9.5
05-01Newsfilter
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
4.0
04-02Benzinga
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews
2.0
04-02Benzinga
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended
Sign Up For More News

FAQ

arrow icon

What is Intra-Cellular Therapies Inc (ITCI) stock price today?

The current price of ITCI is 0 USD — it has decreased -0.04 % in the last trading day.

arrow icon

What is Intra-Cellular Therapies Inc (ITCI)'s business?

arrow icon

What is the price predicton of ITCI Stock?

arrow icon

What is Intra-Cellular Therapies Inc (ITCI)'s revenue for the last quarter?

arrow icon

What is Intra-Cellular Therapies Inc (ITCI)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Intra-Cellular Therapies Inc (ITCI)'s fundamentals?

arrow icon

How many employees does Intra-Cellular Therapies Inc (ITCI). have?

arrow icon

What is Intra-Cellular Therapies Inc (ITCI) market cap?